Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Open Access
- 12 September 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (17) , 5189-5198
Abstract
Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at onset of GVHD quantify GI crypt damage; AA2/3 scores correlate with resistance to treatment and higher NRM. We conducted a multicenter, phase 2 study using natalizumab, a humanized monoclonal antibody that blocks T-cell trafficking to the GI tract through the α4 subunit of α4β7 integrin, combined with corticosteroids as primary treatment for patients with new onset AA2/3 GVHD. Seventy-five patients who were evaluable were enrolled and treated; 81% received natalizumab within 2 days of starting corticosteroids. Therapy was well tolerated with no treatment emergent adverse events in >10% of patients. Outcomes for patients treated with natalizumab plus corticosteroids were compared with 150 well-matched controls from the MAGIC database whose primary treatment was corticosteroids alone. There were no significant differences in overall or complete response between patients treated with natalizumab plus corticosteroids and those treated with corticosteroids alone (60% vs 58%; P = .67% and 48% vs 48%; P = 1.0, respectively) including relevant subgroups. There were also no significant differences in NRM or overall survival at 12 months in patients treated with natalizumab plus corticosteroids compared with controls treated with corticosteroids alone (38% vs 39%; P = .80% and 46% vs 54%; P = .48, respectively). In this multicenter biomarker–based phase 2 study, natalizumab combined with corticosteroids failed to improve outcome of patients with newly diagnosed high-risk GVHD. This trial was registered at www.clinicaltrials.gov as # NCT02133924.Keywords
This publication has 50 references indexed in Scilit:
- Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host DiseaseNew England Journal of Medicine, 2012
- Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivoBlood, 2010
- Matching Methods for Causal Inference: A Review and a Look ForwardStatistical Science, 2010
- Up-Regulation of α4β7 Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study DesignJNCI: Journal of the National Cancer Institute, 2008
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapyBone Marrow Transplantation, 2006
- Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar timeBone Marrow Transplantation, 2005
- In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsetsBlood, 2005
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988